Related Experiment Video

Updated: May 30, 2026

Preparation of Rat Skeletal Muscle Homogenates for Nitrate and Nitrite Measurements
07:19

Preparation of Rat Skeletal Muscle Homogenates for Nitrate and Nitrite Measurements

Published on: July 29, 2021

Nitric oxide inhibits gastric cancer cell growth through the modulation of the Akt pathway

Jianrong Sang1, Yongchang Chen, Yan Tao

  • 1School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu, PR China. sangjianrong@yahoo.com.cn

Molecular Medicine Reports
|July 20, 2011
PubMed

Insights

Nitric oxide (NO) suppresses gastric cancer cell growth by halting the cell cycle. This involves regulating key proteins, potentially through Akt signaling pathways, offering insights into cancer treatment.

Area of Science:

  • Cell Biology
  • Cancer Research
  • Biochemistry

Background:

  • Nitric oxide (NO) plays a dual role in cancer, influencing tumorigenesis, progression, and death.
  • The precise mechanisms by which NO affects tumor cells are complex and not fully elucidated.
  • Understanding NO's impact on cancer cell proliferation is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the direct effects of nitric oxide on gastric cancer cell growth.
  • To elucidate the cell cycle regulatory mechanisms involved in NO-induced growth suppression.
  • To explore the signaling pathways mediating NO's anti-cancer effects in BGC-823 cells.

Main Methods:

  • Treatment of BGC-823 gastric cancer cells with varying concentrations and durations of sodium nitroprusside (SNP).
  • Cell cycle analysis to determine phase arrest.
  • Western blot analysis to assess the expression levels of cell cycle regulatory proteins (p21waf1/cip1, cyclin D1, cyclin E, PCNA) and signaling molecules (phospho-Akt, phospho-ERK).

Main Results:

  • Nitric oxide significantly suppresses BGC-823 cell growth in a dose- and time-dependent manner.
  • NO induces G0/G1 phase arrest by up-regulating p21waf1/cip1 and down-regulating cyclin D1, cyclin E, and PCNA.
  • Exposure to NO leads to decreased phospho-Akt and increased phospho-ERK levels, suggesting Akt signaling pathway inactivation.

Conclusions:

  • Nitric oxide directly inhibits gastric cancer cell proliferation by inducing G0/G1 cell cycle arrest.
  • The observed cell cycle arrest is mediated by the modulation of key cell cycle regulatory proteins.
  • NO-induced growth suppression may involve the inactivation of the Akt signaling pathway, representing a potential mechanism for inhibiting gastric cancer growth.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...